Paper36933639
Harnessing function of EMT in hepatocellular carcinoma: From biological view to nanotechnological standpoint.
Alqurashi YE and 9 others. Environ Res, 2023. Cited by 33 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Harnessing function of EMT in hepatocellular carcinoma: From biological view to nanotechnological standpoint. Papers, record 36933639. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36933639
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Harnessing function of EMT in hepatocellular carcinoma: From biological view to nanotechnological standpoint.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| Epithelial-Mesenchymal Transition | |
| Epithelial Cells | |
| Cell Transformation, Neoplastic | |
| Cell Line, Tumor |
Source PubMed
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42984920 | Small Molecule Targeted Therapy for Hepatocellular Carcinoma: From Multikinase Inhibition to Cancer Stem Cell Eradication Strategies. | Oncol Res | 2026 | https://conductscience.org/library/papers/42984920 | PubMed |
| 42758381 | NHSL3 knockout modulates sorafenib response, growth, and motility in hepatocellular carcinoma cell models. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42758381 | PubMed |
| 41953013 | Investigating the role of the TGF-β-SLC20A1 axis in the spatial heterogeneity of hepatocellular carcinoma through single-cell and spatial transcriptomics. | Front Immunol | 2026 | https://conductscience.org/library/papers/41953013 | PubMed |
| 41879446 | Bee Venom and Cancer: A Mini-review Focusing on Melittin Antitumoral Effects. | Curr Drug Targets | 2026 | https://conductscience.org/library/papers/41879446 | PubMed |
| 41578333 | Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41578333 | PubMed |
| 41572799 | Extracellular Vesicles in Liver Disease: Redefining Diagnostic and Therapeutic Strategies. | Int J Stem Cells | 2026 | https://conductscience.org/library/papers/41572799 | PubMed |
| 41491521 | Integrating single cell- and spatial- resolved transcriptomics unravels the inter-tumor heterogeneity and immunosuppressive landscape in HBV- and Clonorchis sinensis-associated hepatocellular carcinoma. | Mol Cancer | 2026 | https://conductscience.org/library/papers/41491521 | PubMed |
| 41277807 | RBMX2 links Mycobacterium bovis infection to epithelial-mesenchymal transition and lung cancer progression. | Elife | 2025 | https://conductscience.org/library/papers/41277807 | PubMed |
| 41149589 | A Robust Marine Collagen Peptide-Agarose 3D Culture System for In Vitro Modeling of Hepatocellular Carcinoma and Anti-Cancer Therapeutic Development. | Mar Drugs | 2025 | https://conductscience.org/library/papers/41149589 | PubMed |
| 40862712 | Multi-Omic Characterization of Epithelial-Mesenchymal Transition: Lipidomic and Metabolomic Profiles as Key Markers of TGF-β-Induced Transition in Huh7 Hepatocellular Carcinoma. | Cells | 2025 | https://conductscience.org/library/papers/40862712 | PubMed |
| 40556662 | Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma. | BME Front | 2025 | https://conductscience.org/library/papers/40556662 | PubMed |
| 40312502 | RGS14 promotes the progression of hepatocellular carcinoma by activating the cAMP/PKA/CREB signaling pathway. | J Cancer Res Clin Oncol | 2025 | https://conductscience.org/library/papers/40312502 | PubMed |
| 40260291 | Mechanistic studies and therapeutic potential of angiopoietin in head and neck tumor angiogenesis. | Front Oncol | 2025 | https://conductscience.org/library/papers/40260291 | PubMed |
| 40192866 | Insights into the history and trends of nanotechnology for the treatment of hepatocellular carcinoma: a bibliometric-based visual analysis. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40192866 | PubMed |
| 40038747 | MAZ-mediated N6-methyladenosine modification of ZEB1 promotes hepatocellular carcinoma progression by regulating METTL3. | J Transl Med | 2025 | https://conductscience.org/library/papers/40038747 | PubMed |
| 39764737 | The miRNA-mRNA Regulatory Network in Human Hepatocellular Carcinoma by Transcriptomic Analysis From GEO. | Cancer Rep (Hoboken) | 2025 | https://conductscience.org/library/papers/39764737 | PubMed |
| 39532948 | A predicted epithelial-to-mesenchymal transition-associated mRNA/miRNA axis contributes to the progression of diabetic liver disease. | Sci Rep | 2024 | https://conductscience.org/library/papers/39532948 | PubMed |
| 39498055 | Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights. | Heliyon | 2024 | https://conductscience.org/library/papers/39498055 | PubMed |
| 39267682 | Nrf2 in human cancers: biological significance and therapeutic potential. | Am J Cancer Res | 2024 | https://conductscience.org/library/papers/39267682 | PubMed |
| 39062458 | AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment. | Biomolecules | 2024 | https://conductscience.org/library/papers/39062458 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| SNAI1 | 6615 | PubTator's text mining | https://conductscience.org/library/genes/6615 | NCBI Gene |
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
| TWIST1 | 7291 | PubTator's text mining | https://conductscience.org/library/genes/7291 | NCBI Gene |
| ZEB1 | 6935 | PubTator's text mining | https://conductscience.org/library/genes/6935 | NCBI Gene |
| ZEB2 | 9839 | PubTator's text mining | https://conductscience.org/library/genes/9839 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36933639
GET https://conductscience.org/api/papers/v1/36933639/cited_by?page=2